AACR: Lengthy Survival in Some Receiving NSCLC Vaccine

Share this article:
AACR: Lengthy Survival in Some Receiving NSCLC Vaccine
AACR: Lengthy Survival in Some Receiving NSCLC Vaccine

(HealthDay News) – Use of belagenpumatucel-L, a therapeutic vaccine comprised of four tumor growth factor-β2 antisense gene-modified allogeneic non-small-cell lung cancer (NSCLC) cell lines, is associated with encouraging long-term survival for patients with Stage IIIB and IV NSCLC, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 31–April 4 in Chicago.

Lyudmila Bazhenova, MD, from the San Diego Moores Cancer Center in La Jolla, CA, and colleagues conducted a long-term follow-up of a Phase 2 trial of belagenpumatucel-L. The clinical trial enrolled 75 patients, two with Stage II, 12 Stage IIIA, 15 Stage IIIB, and 46 with Stage IV NSCLC, who were randomly allocated into three dose cohorts (1.25, 2.5, or 5 × 107 cells/injection). Patients were followed for a median of 14.5 months, and those with stable disease were followed for 44 months.

The researchers found that the one-, two-, and five-year survival rates were 55%, 35%, and 20%, respectively, with median survival of 14.5 months. Patients with stage IIIB and IV NSCLC enrolled into the second and third dose cohorts had one-, two-, and five-year survival rates of 61%, 41%, and 18%, respectively, with median survival of 15.9 months. Stage IIIB and IV patients with nonprogressive disease following frontline chemotherapy had a median survival of 44.4 months and five-year survival of 50%, whereas those who progressed had median survival of 14.1 months and five-year survival of 9.1%.

"Based on these data, we have instituted an international, randomized, pivotal Phase 3 trial to evaluate the efficacy of belagenpumatucel-L in a maintenance setting in stage III/IV NSCLC patients," the authors write.

The study was sponsored by NovaRx Corporation, the manufacturer of belagenpumatucel-L (Lucanix); several authors are employees of NovaRx.

Abstract No. 5367
More Information

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs